Armata Pharmaceuticals (Armata Pharmaceuticals) Intrinsic Value: DCF (Dividends Based) : $ (As of May. 23, 2024)

---

Armata Pharmaceuticals Intrinsic Value: DCF (Dividends Based) Chart

---

Competitive Comparison of Armata Pharmaceuticals's Intrinsic Value: DCF (Dividends Based)

For the Biotechnology subindustry, Armata Pharmaceuticals's Price-to-DCF (Dividends Based), along with its competitors' market caps and Price-to-DCF (Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

---

Armata Pharmaceuticals's Price-to-DCF (Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Price-to-DCF (Dividends Based) distribution charts can be found below:

* The bar in red indicates where Armata Pharmaceuticals's Price-to-DCF (Dividends Based) falls into.

---

Armata Pharmaceuticals Intrinsic Value: DCF (Dividends Based) Calculation

This is the intrinsic value calculated from the Discounted Dividend Model with default parameters. The calculation method is the same as Discounted Cash Flow model except adjusted dividend are used in the calculation instead of free cash flow. This is the default method of calculation with GuruFocus DCF calculator.

Usually a two-stage model is used in calculating the intrinsic value with discounted cash flow model. The first stage is called growth stage; the second is called the terminal stage. In the growth stage the company grows at a faster rate. Because it cannot grow at that rate forever, a lower rate is used for the terminal stage.

GuruFocus DDM calculator is a two-stage model. The default values are defined as:

1. Discount Rate: d = 11%
A reasonable discount rate assumption should be at least the long term average return of the stock market, which can be estimated from risk free rate plus risk premium of stock market. GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate and rounded up to the nearest integer. It is updated daily. The current risk-free rate is 4.43%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default. Then we added a risk premium of 6% to get the estimated discount rate. Some investors use their expected rate of return, which is also reasonable. A typical discount rate can be anywhere between 6% - 20%.

2. Dividend Growth Rate in the growth stage: g1 = %
The Growth Rate in the growth stage is initially set as the default 10-Year Dividend Growth Rate. In cases where the 10-year growth rate is unavailable, it defaults to using the 5-Year Dividend Growth Rate. If both the 10-year and 5-year growth rates are unavailable, the system defaults to the 3-Year Dividend Growth Rate.
However, it's important to note that there is a growth rate range. If the calculated growth rate exceeds 20%, it will be capped at 20%. Conversely, if the calculated growth rate falls below 5%, it will be adjusted to 5% to maintain a reasonable range.
=>

3. Years of Growth Stage: y1 = 10

4. Terminal Growth Rate: g2 = 4%

5. Dividends per Share: adjusted dividends per share = $.
GuruFocus uses adjusted dividends per share by default to ensure that the valuation reflects the total value of the company, as the actual dividend is only a portion of the total value.

All of the default settings can be changed in the DCF calculator and the results are calculated automatically.

Armata Pharmaceuticals's Intrinsic Value: DCF (Dividends Based) for today is calculated as:

set x = (1+g1)/(1+d) = (1+)/(1+0.11) =
and y = (1+g2)/(1+d) = (1+)/(1+0.11) =

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

---

Armata Pharmaceuticals  (AMEX:ARMP) Intrinsic Value: DCF (Dividends Based) Explanation

Unlike valuation methods such as Net Current Asset Value, Tangible Book per Share, Graham Number, Median PS Value etc, discounted Dividends model evaluates the companies based on their power of future dividend distribution instead of their assets.

---

Be Aware

What you need to know about Discounted Dividends model:

1. The Discounted Dividends model evaluates a company based on its future dividends distribution power
2. Dividend growth is taken into account; therefore a company with a higher dividend growth rate is worth more if everything else is the same.
3. Since we are projecting future growth, it is assumed that the company will grow at the same rate as it did during the past 10 years. Therefore this model works better for the companies with consistently steady dividends distributed.
4. The Discounted Dividends model works poorly for inconsistent dividends distributor like high growth companies.
5. Your expected return from the investment is a reasonable discount rate assumption.
6. A larger margin of safety should be required for companies with less dividends distributed.

You can screen for stocks that trade below their Intrinsic Value: DCF (FCF Based) and Intrinsic Value: DCF (Earnings Based) and Intrinsic Value: DCF (Dividends Based) with the GuruFocus All-in-One Screener. Companies with a high Predictability Rank that trade at a discount to their Intrinsic Value: DCF (FCF Based) and Intrinsic Value: DCF (Earnings Based) can be found in the screen of Undervalued Predictable Companies.

---

Armata Pharmaceuticals Intrinsic Value: DCF (Dividends Based) Related Terms

Thank you for viewing the detailed overview of Armata Pharmaceuticals's Intrinsic Value: DCF (Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Predictability Rank Intrinsic Value: Projected FCF Intrinsic Value: DCF (FCF Based) Intrinsic Value: DCF (Earnings Based) Margin of Safety % (DCF Dividends Based) Margin of Safety % (DCF FCF Based) Margin of Safety % (DCF Earnings Based) 5-Year Dividend Growth Rate Dividends per Share

---

Armata Pharmaceuticals (Armata Pharmaceuticals) Business Description

Executives

Richard Rychlik	officer: Corporate Controller and PFO	5005 MCCONNELL AVENUE, LOS ANGELES CA 90066
Deborah Birx	director, officer: Chief Executive Officer	3300 LOWELL STREET NW, WASHINGTON DC 20008
Julianne Averill	officer: Chief Financial Officer	361 NEWBURY STREET, SUITE 500, BOSTON MA 02115
Erin Butler	officer: Vice President,Finance & Admin	4375 LOMA RIVIERA COURT, SAN DIEGO CA 92110
Theravance Inc	director, 10 percent owner	1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Jules Haimovitz	director	601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
Innoviva Strategic Opportunities Llc	director, 10 percent owner	1209 ORANGE STREET, WILMINGTON DE 19801
Robin Kramer	director	999 VANDERBILT BEACH ROAD, 3RD FLOOR, NAPLES FL 34109
Steven Robert Martin	officer: Chief Financial Officer	11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kostas D Odysseas	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger	director	C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jeremy Curnock Cook	director	TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101
Michael S Perry	director	C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Todd C. Peterson	director	C/O ARMATA PHARMACEUTICALS, INC., 4503 GLENCOE AVENUE, MARINA DEL REY CA 90292
H Stewart Parker	director